Yazar "Hacioglu, Sibel" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim Yok
    Öğe
    Multicenter retrospective analysis regarding the clinical manifestations and treatment results in patients with hairy cell leukemia: twenty-four year Turkish experience in cladribine therapy
    (Wiley, 2015) Hacioglu, Sibel; Bilen, Yusuf; Eser, Ali; Sivgin, Serdar; Gurkan, Emel; Yildirim, Rahsan; Aydogdu, Ismet
    In this multicenter retrospective analysis, we aimed to present clinical, laboratory and treatment results of 94 patients with Hairy cell leukemia diagnosed in 13 centers between 1990 and 2014. Sixty-six of the patients were males and 28 were females, with a median age of 55. Splenomegaly was present in 93.5% of cases at diagnosis. The laboratory findings that came into prominence were pancytopenia with grade 3 bone marrow fibrosis. Most of the patients with an indication for treatment were treated with cladribine as first-line treatment. Total and complete response of cladribine was 97.3% and 80.7%. The relapse rate after cladribine was 16.6%, and treatment related mortality was 2.5%. Most preferred therapy ( 95%) was again cladribine at second-line, and third line with CR rate of 68.4% and 66.6%, respectively. The 28-month median OS was 91.7% in all patients and 25-month median OS 96% for patients who were given cladribine as first-line therapy. In conclusion, the first multicenter retrospective Turkish study where patients with HCL were followed up for a long period has revealed demographic characteristics of patients with HCL, and confirmed that cladribine treatment might be safe and effective in a relatively large series of the Turkish study population. Copyright (C) 2014 John Wiley & Sons, Ltd.
  • Küçük Resim Yok
    Öğe
    Stem cell mobilization kinetics in elderly patients with multiple myeloma
    (Pergamon-Elsevier Science Ltd, 2018) Dogu, Mehmet Hilmi; Batgi, Hikmetullah; Erkurt, Mehmet Ali; Hacioglu, Sibel; Tekgunduz, Emre; Kaya, Emin; Iskender, Dicle
    In this study, we aimed to investigate whether the procedure and product kinetics differ according to age groups in advanced-age MM patients who underwent autologous HSCT. 59 patients who underwent autologous HSCT were retrospectively analyzed. Then, the patients were divided into two groups as 60-65 years and >= 65 years. It was significantly lower in >= 65 years group (p=0.008) and proportionally, the procedure duration was also significantly shortened in this group (p=0.013). Total number of collected CD34 positive stem cells was 6.20 x 106 (+/- 3.83) in 60-65 years group while it was 5.51 x 106 (+/- 2.48) in >= 65 years group with no statistically significant difference. (p=0.825). In conclusion, there was no significant difference in terms of the number of collected CD34-positive stem cells in this study that investigates the mobilization data, procedure and product kinetics, we think that successful stem cell mobilization can be performed in appropriately selected patients regardless of age. (C) 2018 Elsevier Ltd. All rights reserved.
  • Küçük Resim
    Öğe
    Stem cell mobilization kinetics in elderly patients with multiple myeloma
    (Pergamon-elsevıer scıence ltd, the boulevard, langford lane, kıdlıngton, oxford ox5 1gb, england, 2018) Dogu, Mehmet Hilmi; Batgi, Hikmetullah; Erkurt, Mehmet Ali; Hacioglu, Sibel
    In this study, we aimed to investigate whether the procedure and product kinetics differ according to age groups in advanced-age MM patients who underwent autologous HSCT. 59 patients who underwent autologous HSCT were retrospectively analyzed. Then, the patients were divided into two groups as 60-65 years and >= 65 years. It was significantly lower in >= 65 years group (p=0.008) and proportionally, the procedure duration was also significantly shortened in this group (p=0.013). Total number of collected CD34 positive stem cells was 6.20 x 106 (+/- 3.83) in 60-65 years group while it was 5.51 x 106 (+/- 2.48) in >= 65 years group with no statistically significant difference. (p=0.825). In conclusion, there was no significant difference in terms of the number of collected CD34-positive stem cells in this study that investigates the mobilization data, procedure and product kinetics, we think that successful stem cell mobilization can be performed in appropriately selected patients regardless of age. (C) 2018 Elsevier Ltd. All rights reserved.